NCT07047521View on ClinicalTrials.gov

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

November 17, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

July 30, 2027

Conditions
Dengue Fever
Interventions
BIOLOGICAL

Tetravalent Dengue Vaccine (TDV)

TDV subcutaneous injection

Trial Locations (5)

2019

Emeritus Research Sydney, Botany

2150

Paratus Clinical Research Western Sydney, Blacktown

2259

Paratus Clinical Research Central Coast, Kanwal

3124

Emeritus Research Camberwell (Melbourne), Camberwell

3153

Veritus Research, Bayswater

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY